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Constitutively Active Protein Kinase B Enhances Lck and Erk
Activities and Influences Thymocyte Selection and Activation1
Shin-Young Na,* Amiya Patra,* Yvonne Scheuring,* Alexander Marx,† Mauro Tolaini,‡
Dimitris Kioussis,‡ Brian Hemmings,§ Thomas Hu¨nig,* and Ursula Bommhardt2*
Protein kinase B (PKB), a serine threonine kinase is critically involved in cellular proliferation and survival. To characterize its
role in T cell development in vivo, we have analyzed transgenic mice that express a membrane-targeted constitutively active
version of PKB (myr PKB) in thymocytes and peripheral T cells. We report that myr PKB renders proliferative responses of
thymocytes more sensitive to TCR signals by increased and sustained activation of Src kinase Lck and the extracellular signal-
regulated kinase/mitogen-activated protein kinase pathway. In addition, the proliferative response of myr PKB T cells is relatively
independent of calcium mobilization and calcineurin activity. We also find that myr PKB enhances phosphorylation of glycogen
synthase kinase 3, a negative regulator of NFAT and T cell activation, and the recruitment of the adapter protein Cbl-c. Inter-
estingly, we demonstrate that upon TCR/CD3 stimulation of wild-type T cells PKB is translocated into lipid rafts, adding a new
role for PKB in TCR-initiated signalosome formation in T cell activation. Localization of transgenic PKB in lipid rafts could
contribute to the higher TCR sensitivity of myr PKB thymocytes which is reflected in an increase in positive selection toward the
CD4 lineage and variable effects on negative selection depending on the model system analyzed. Thus, our observations clearly
indicate a cross-talk between PKB and important signaling molecules downstream of TCR that modulate the thresholds of
thymocyte selection and T cell activation. The Journal of Immunology, 2003, 171: 1285–1296.
C lonal selection of immature T cells occurs at theCD4CD8 (double-positive (DP))3 stage. Signalingmolecules central in determining the cell fate of DP thy-
mocytes include the Src family kinase Lck and the mitogen-acti-
vated protein kinases (MAPKs). The Ras-Raf-MEK-extracellular
signal-regulated kinase (Erk) signaling cascade in particular has
been shown to regulate positive and negative selection as well as
CD4 vs CD8 lineage choice (1). It is largely unknown how the
MAPK pathways cross-talk with other signaling cascades. Phos-
phatidylinositol-3 kinase (PI3K) signaling has been found in dif-
ferent cell systems to be fundamental in regulation of cell growth,
differentiation, survival, and adhesion/migration (2). A prominent
target of PI3K is protein kinase B (PKB), which mediates many
cellular responses of PI3K including protection against apoptosis
(3–5). A cross-talk between the PI3K-PKB and Raf-MEK-Erk
pathways has been reported on multiple levels. Whereas some
studies in cell lines show that PI3K/PKB enhances or synergizes
with Raf-MEK-Erk signaling (6, 7), other studies, mainly in mus-
cle cells, suggest that PKB abrogates Raf activity on downstream
targets (8, 9); these discrepancies probably reflect differences in
cell type and the differentiation state of the cell.
PKB, a serine threonine kinase, is recruited by its pleckstrin
homology domain to membrane-localized phosphatidylinositol
3,4,5-triphosphate and PtdIns(3,4)P2, the second messenger prod-
ucts of PI3-kinase. Membrane localization of PKB leads to its
activation via phosphorylation at serine 473 in the C-terminal reg-
ulatory domain and at threonine 308 in the catalytic domain me-
diated by phosphoinositide-dependent protein kinases. Activated
PKB dissociates from the plasma membrane and phosphorylates a
variety of substrates in the cytoplasm and nucleus. PKB can be
regulated either directly at the plasma membrane by interaction
with several proteins such as the C-terminal modulator protein (10)
or indirectly as by the lipid phosphatase and tensin homologue
(PTEN), which reduces the amounts of PtdInsP3 at the membrane.
Dysregulation of PTEN is associated with development of a vari-
ety of human cancers, autoimmune disorders, and loss of tolerance
(11–15) and increased PKB activity was implicated in most of
these disease phenotypes. Two of the three PKB genes have so far
been disrupted in the mouse germline. PKB knockout mice are
viable but their growth is retarded, and PKB-deficient thymocytes
show increased apoptosis (16). PKB-null mice are also viable and
show defects in insulin signaling (17). In lymphocytes PKB is
activated by cytokines (18), TCR signaling (19), CD28 costimu-
lation (20), integrin-linked kinase (21), CD38 (22), or ICAM-2
(23), among others. The antiapoptotic proteins Bcl-xL and Bcl-2
and the transcription factor NF-B are key targets of PKB in T
cells, resulting in enhanced T cell survival (24, 25). Besides the
prominent role of PKB in regulating cell survival or cell size (26,
27), recent work has highlighted PKB as a potentiator of prolifer-
ation. PKB effectors involved in cell cycle regulation include pro-
teins like E2F and cyclins (28, 29) and the transcription factors of
Institutes of *Virology and Immunobiology and †Pathology, University of Wu¨rzburg,
Wu¨rzburg, Germany; ‡Division of Molecular Immunology, National Institute for
Medical Research, Mill Hill, London, United Kingdom; and §Friedrich Miescher In-
stitute, Basel, Switzerland
Received for publication October 31, 2002. Accepted for publication June 2, 2003.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by a grant from the Deutsche Forschungsgemeinschaft to
the Forschergruppe FOR 303/2-1 TP A3.
2 Address correspondence and reprint requests to Dr. Ursula Bommhardt, Institute of
Virology and Immunobiology, University of Wu¨rzburg, Versbacher Strasse 7,
D-97078 Wu¨rzburg, Germany. E-mail address: Bommhardt@vim.uni-wuerzburg.de
3 Abbreviations used in this paper: DP, double-positive; MAPK, mitogen-activated
protein kinase; PI3K, phosphatidylinositol-3 kinase; PKB, protein kinase B; PTEN,
phosphatase and tensin homologue; CsA, cyclosporin A; HA, hemagglutinin; DN,
double-negative; SP, single-positive; GSK3, glycogen synthase kinase 3; LAT, linker
for activation of T cells; LN, lymph node; 7-AAD, 7-amino-actinomycin D; Erk,
extracellular signal-regulated kinase; MEK, mitogen-activated protein/Erk kinase;
HSA, heat-stable Ag; SAg, superantigen; PAG, phosphoprotein associated with gly-
cosphingolipid-enriched microdomains.
The Journal of Immunology
Copyright © 2003 by The American Association of Immunologists, Inc. 0022-1767/03/$02.00
 at U
niv of Plym
outh Lib Serv/Libr/Em
m
a Brew
er on February 10, 2016
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
the forkhead family (30). Both, inhibition of apoptosis and in-
creased cellular proliferation are two distinct, although intercon-
nected, mechanisms through which PKB promotes cellular trans-
formation and cancer progression.
To address the effects of PKB on developmental events in vivo,
we generated transgenic mice harboring a constitutively active
PKB by means of a myristoylation tag (myr PKB) under the hu-
man CD2 promoter leading to expression of myr PKB in thymo-
cytes and mature T cells. We found that overexpression of myr
PKB promotes the efficiency of positive selection fostering selec-
tion of CD4 T cells in TCR transgenic mice, most notably in
mice bearing TCRs with MHC class I-restricted specificity. In neg-
ative selection myr PKB either reduced, enhanced, or had no ef-
fect, depending on the experimental model investigated. Further-
more, myr PKB transgenic thymocytes showed a reduced
dependence on calcium mobilization and a higher resistance to
inhibition by the immunosuppressants cyclosporin A (CsA) and
FK506 in T cell activation. Further studies revealed that TCR/CD3
stimulation leads to recruitment of endogenous active PKB into
detergent insoluble glycolipid-rich membrane domains, so-called
lipid rafts. Localization of myr PKB in lipid rafts could contribute
to the enhanced activation of TCR downstream signaling mole-
cules, whose differential activities contribute to the altered pheno-
type in T cell selection and activation in myr PKB transgenic mice.
Materials and Methods
Generation of transgenic mice
Construction of human PKB cDNA harboring the hemagglutinin (HA)
epitope tag and the lck myristoylation/palmitoylation signal (MGCWCSS
NPEDD) for membrane targeting has been described previously (31). Myr-
HA-PKB cDNA (myr PKB) was inserted into the EcoRI site of the human
CD2 minigene cassette (32). The linearized hCD2-myr-HA-PKB fragment
was microinjected into fertilized eggs from (CBA/J  C57BL/10) F1 an-
imals. Transgenic founder mice were identified by DNA slot blots using a
[32P]DNA probe specific for the human CD2 cassette. Stable PKB trans-
genic lines were established by crossing transgenic mice to C57BL/6 mice.
Transgenic mice were identified by PCR of genomic tail DNA. Mice used
throughout the study were offspring from two founder lines (PKB2 and
PKB6) which were crossed to C57BL/6 mice for at least three generations.
Mice used were 6–8 wk old if not specified otherwise. No transformation
was observed in myr PKB heterozygous mice aged up to 8 mo.
Mice
OT1 (33), OT2 (34), HY (35) TCR transgenic mice and DBA/2 and CBA/J
mice (Charles River Breeding Laboratories, Wiga, Sulzfeld, Germany)
were crossed with myr PKB transgenic mice.
Isolation of cells and proliferation
Thymi were forced through a fine mesh filter to obtain single cell suspen-
sions. For proliferation assays, total thymocytes (1 106) were cultured in
96-well plates in triplicates in complete RPMI 1640 supplemented with
10% FCS. Cells were stimulated with plate bound anti-CD3 mAb
(145.2C11; BD PharMingen, San Diego, CA) or with PMA and ionomycin
(both Calbiochem, San Diego, CA) for the indicated time points. CsA,
FK506, PD98059, and PP1 (all from Calbiochem) were added at the be-
ginning of culture at concentrations as stated. On day 2, cells were pulsed
with 1 Ci [3H]thymidine/well (ICN Pharmaceuticals, Asse-Relegem, Bel-
gium) and harvested after 10–16 h.
Flow cytometric analysis
Abs were obtained from BD PharMingen as FITC-, PE- or biotin-labeled
conjugates or were prepared in our own laboratory (Institute of Virology
and Immunobiology, University of Wu¨rzburg, Wu¨rzburg, Germany): CD4
(GK1.5), CD8 (YTS169.4), CD69 (H1.2F3), CD5 (53-7.3), TCR (H57-
597), heat-stable Ag (HSA) (M1/69), CD44 (IM7), CD25 (7D4), V5
(MR9-4), V8 (F23.1), V11 (RR3-15), V2 (B20.1). Biotinylated Abs
were revealed with streptavidin-CyChrome (BD PharMingen). T3.70 mAb
specific for the HY TCR transgenic V-chain was a kind gift from Dr. T.
Miyazaki (Center for Immunology, University of Texas Southwestern
Medical Center, Dallas, TX). Cells were stained using standard procedure
and were analyzed on a FACScan or FACSCalibur (BD Biosciences,
Mountain View, CA) using CellQuest software. For FACS analysis of
double-negative (DN) cells, DP and mature single-positive (SP) cells were
depleted by treatment with anti-CD4 (RL174.2) and anti-CD8 (3.168.1)
supernatant and Low-Tox rabbit complement (Cedarlane Laboratories,
Hornby, Ontario, Canada).
Western blot and Lck immune complex kinase assay
Freshly isolated thymocytes (2–4  106) were lysed immediately or
starved for 2 h in 1% FCS medium before stimulation with anti-CD3 mAb
(145.2C11, 30 g/ml). Cells were lysed in buffer containing 20 mM
HEPES, 2 mM EGTA, 50 mM -glycerophosphate, 1% Triton X-100, 10%
glycerol, 50 mM NaF, 0.04% azide, 1 mM DTT, 1 mM orthovanadate, 2
M leupeptin, 0.4 mM PMSF for 30 min on ice. Protein extracts from
2–4  106 cells were separated on 8–12% SDS-PAGE and electroblotted
to nitrocellulose membranes. Specific proteins were detected by Western
blot analysis using the following primary Abs: anti-PKB, anti-phospho-
PKB (Ser473), anti-phospho-Erk, anti-phospho-glycogen synthase kinase 3
(GSK3) , anti-phosphotyrosine (4G10), anti-phospho-Lck (Tyr394), anti-
phospho-c-Raf (Ser259) (New England Biolabs, Beverly, MA), anti-Lck
(36), anti-Cbl-c, and anti-linker for activation of T cells (LAT) (Santa Cruz
Biotechnology, Santa Cruz, CA). Primary Abs were detected by goat anti-
rabbit (1/3000; Santa Cruz Biotechnology), goat anti-mouse (1/3000;
Chemicon, Temecula, CA) or rabbit anti-goat (1/5000; Chemicon) Abs
coupled with HRP and ECL (Pierce, Milwaukee, WI). Blots were reprobed
with anti-actin Ab (Santa Cruz Biotechnology) to control protein loading.
For Lck kinase assays, 5  107 freshly isolated thymocytes were lysed
immediately or starved for 2 h in 1% FCS medium before stimulation with
anti-CD3 mAb (145.2C11, 30 g/ml) for the indicated time points. Cells
were lysed in 500 l of Brij-98 lysis buffer (1% Brij-98 in TNE buffer: 25
mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Pefabloc, 5 mM
iodoacetamide, 1 mM Na3VO4, 1 mM NaF) and Lck was immunoprecipi-
tated with anti-Lck Ab (36) and protein G-Sepharose (Amersham Bio-
sciences, Freiburg, Germany). Lck precipitates were washed two times
with lysis buffer and kinase assay buffer (0.1% Brij-98, 25 mM HEPES pH
7.4) before incubation with 30 l of assay buffer containing 10 mM MnCl2,
5 Ci [-32P]ATP (3000 Ci/mmol; Amersham Biosciences) and acidified
enolase (5 g; Sigma-Aldrich, Taufkirchen, Germany) for 20 min at 30°C.
After addition of 30 l of 2 sample reducing buffer, Lck activation was
detected by 10% SDS-PAGE and exposure to x-ray film.
Preparation of glycolipid-enriched membrane microdomain
fractions
Freshly isolated thymocytes (1  108) or purified CD4 T cells from
lymph nodes in 200 l of PBS were treated with 200 l of cold Brij-98
lysis buffer (0.1% Brij-98 in TNE buffer: 25 mM Tris, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 1 mM Pefabloc, 5 mM iodoacetamide, 1 mM
Na3VO4, 1 mM NaF). The lysate was mixed with 400 l of 80% sucrose
in TNE buffer. The solution was overlaid with 2.8 ml of 30% sucrose in
TNE buffer followed by 400 l of TNE buffer and centrifuged at
250,000  g for 22 h at 4°C. Proteins in the four harvested fractions were
precipitated with acetone, and 50 l (fractions 1–3) or 250 l (fraction 4)
of SDS-PAGE sample buffer were added to the precipitates. Twenty mi-
croliter samples were resolved by SDS-10% PAGE and Western blotted.
Based on localization of LAT, the top fractions (1, 2) were designated the
detergent insoluble raft microdomain fraction and the bottom fractions (3,
4), containing the majority of total protein, were designated detergent sol-
uble. For activation of CD4 T cells, 1  108 cells were stimulated with
anti-CD3 mAb (145.2C11, 10 g) and anti-hamster IgG (10 g; Sigma-
Aldrich) for 30 min at 37°C. Raft preparation of stimulated cells was as
described for thymocytes.
Measurement of apoptosis
Total thymocytes or purified lymph node (LN) CD4 T cells (each 1 
106/ml) from wild-type and myr PKB mice were cultured in RPMI 1640
with different concentrations of FCS or treated with various apoptotic stim-
uli as indicated. Cell viability was measured at the indicated time points by
annexin V-FITC (BD PharMingen) and 7-amino-actinomycin D (7-AAD;
Sigma-Aldrich) staining and the percentage of live 7-AAD- and annexin
V-negative cells was determined. Apoptosis was induced with C2-cer-
amide, dexamethasone (both from Sigma-Aldrich), anti-fas mAb (Jo2; BD
PharMingen), etoposide, or PMA (both Calbiochem). Apoptosis of thymo-
cytes from OT1 and OT2 mice and crosses with myr PKB mice was studied
by adding OVA peptide 257–264 (33) or 323–339 (34) to 5  105 cells/
well, respectively, in concentrations as indicated. In case of OT2 TCR
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bearing mice irradiated splenic B cells (1  106 cells/well) were added
as APCs.
Results
Generation of transgenic mice expressing myr PKB in
lymphocytes
To investigate the role of PKB in T cell development, we estab-
lished transgenic mouse lines expressing a human myr PKB
cDNA (31) under the control of the human CD2 promoter and
locus control region (Fig. 1A) (32). Of six transgenic founder lines,
three lines (PKB 1, 2, and PKB 6) were crossed to the C57BL/6
background. Analysis of all three lines showed comparable results,
with PKB 6 and PKB 2 being used throughout this study. Myr
PKB expression in thymocytes and peripheral CD4 and CD8 T
cells was determined by Western blots using anti-PKB and anti-
phospho-PKB (Ser473) Abs (Fig. 1, B and C). The kinase activity
of myr PKB was verified for splenic CD4 T cells in kinase assays
as shown previously (37). All mice used in this study were het-
erozygous for myr PKB (PKB/).
Selective accumulation of CD4 T cells in myr PKB mice
First, we examined the cellular composition of thymus, spleen, and
LNs from myr PKB transgenic and wild-type mice of different
ages (Fig. 2 and Table I). The composition of thymocyte subsets
from young (4–12 wk of age) myr PKB transgenic mice was com-
parable to that of littermate control mice or showed a moderate
increase in CD4 and CD8 SP T cells. A reduction in the number of
DP thymocytes (to 60% of wild-type mice) was prominent in
aged mice (3–12 mo of age) and resulted in an overall reduction in
thymocyte cellularity. The development of DP thymocytes to ma-
ture SP thymocytes is associated with a series of phenotypic
changes triggered by the TCR that can be defined using Abs re-
active with the TCR, CD5, and CD69 Ags (38–40). Typically, a
small percentage of DP thymocytes express higher levels of these
markers which are putative indicators for cells that have received
either positive (41–43) or negative selection (44) signals in re-
sponse to TCR engagements. Although thymi from myr PKB mice
were grossly normal in size and morphology, a more detailed anal-
ysis revealed that myr PKB DP thymocytes have a higher percent-
age of cells that have up-regulated TCR, CD5, and CD69 expres-
sion (Fig. 2A). This suggests that in PKB transgenic mice, more
DP cells receive signals that qualify them for further differentiation
or induction of apoptosis. Analysis of T cell subpopulations in the
spleen and lymph nodes in PKB transgenic mice (Fig. 2B and
Table I) showed that the CD4 compartment was selectively en-
larged, with 2- to 3-fold more splenic CD4 T cells, whereas
CD8 T cells were reduced with age. A greater expansion or ac-
cumulation of CD4 T cells led to an increase in the CD4:CD8
ratio which was 5:1 in young mice (4–12 wk) and 11:1 in older
mice (3–12 mo). Thus, myr PKB has differential effects on the
homeostasis and/or generation of CD4 and CD8 T cells leading
to a preferential increase in the peripheral CD4 T cell compart-
ment concomitant with a decline in the CD8 T cell population.
Myr PKB thymocytes are hyperreactive to TCR stimulation and
less sensitive to inhibition by CsA
To correlate the change in the level of PKB activity to functional
responses, we analyzed the proliferative potential of thymocytes in
response to immobilized anti-CD3 mAb and to the pharmacolog-
ical agents PMA and ionomycin, known to activate protein kinase
C and to induce calcium flux, respectively. As shown in Fig. 3A,
stimulation of thymocytes with different concentrations of anti-
CD3 mAb resulted in higher [3H]thymidine incorporation in myr
PKB thymocytes. Astonishingly, thymocytes from myr PKB mice
were capable to proliferate in response to PMA only, i.e., in the
absence of the Ca2 fluxing agent ionomycin (Fig. 3B), whereas
the two populations showed equivalent responses to stimulation
with PMA plus ionomycin. Moreover, in the case of transgenic
mice, the proliferative responses induced by anti-CD3 mAb, as
well as those induced by PMA or PMA/ionomycin, were less sen-
sitive to inhibition by the calcineurin inhibitors CsA or FK506 than
those of wild-type thymocytes which were totally abolished (Fig.
3B). In addition, when TCR-induced signaling was blocked by
mitogen-activated protein/Erk kinase (MEK) inhibitor PD98059
(Fig. 3C) or Src-kinase inhibitor PP1 (Fig. 3D), myr PKB thymo-
cytes again were more resistant to inhibition requiring 5- to 8-fold
higher concentrations of inhibitor to achieve 50% inhibition of
maximal proliferation. Thus, myr PKB synergizes with PMA to
allow proliferation without a calcium signal and confers higher
reactivity to limiting TCR signals coupled with CsA resistance.
Similar results were obtained for peripheral CD4 and CD8 T
cells (data not shown).
Effects of myr PKB on survival of thymocytes and T cells
Next, we tested the response of thymocytes and peripheral T cells
to various apoptotic stimuli. Apoptosis of thymocytes from young
mice (6 wk) was assayed after serum withdrawal or treatment with
PMA, ionomycin, anti-CD3, or anti-fas mAbs, dexamethasone,
etoposide, or UV irradiation (Fig. 4A). For most treatments, the
survival of myr PKB thymocytes was only slightly enhanced or
identical with wild-type cells. Survival was more significantly in-
creased in the case of dexamethasone treatment. Titration of ap-
optosis-inducing reagents and measurement of survival on day 2
FIGURE 1. Generation of PKB transgenic mice. A, Schematic repre-
sentation of the myr PKB transgenic construct. B and C, Expression of myr
PKB in thymocytes and peripheral T cells. B, Thymocytes from wild-type
(wt) and myr PKB transgenic lines (tg) were analyzed by Western blot
using anti-PKB and anti-phospho-PKB (Ser473) Abs. Results are shown for
three different transgenic lines, PKB 2, 6, and 1. Upper bands correspond
to transgenic myr PKB, lower bands to endogenous (end) PKB. Anti-actin
Ab was used to control equal protein loading. C, Western blot analysis for
phospho-PKB (Ser473) expression in peripheral CD4 and CD8 T cells
from wild-type and myr PKB transgenic mice.
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(data not shown) reflected the differences observed as shown in
Fig. 4A. When peripheral CD4 T cells were analyzed (Fig. 4B),
survival and resistance to apoptosis after treatment with ceramide,
dexamethasone, UV or gamma irradiation was distinctly higher in
myr PKB CD4 T cells. This indicates that myr PKB activity
delivers stronger survival signals for mature peripheral T cells than
for thymocytes.
Because aged myr PKB mice showed a reduction of DP cells,
we analyzed the apoptotic response of thymocytes from 7-mo-old
mice (Fig. 4C). In contrast to young mice, DP thymocytes from
aged myr PKB mice survived less well after serum withdrawal,
anti-CD3 and anti-fas mAb, or etoposide treatment. Sensitivity to
dexamethasone treatment and PMA stimuli were comparable to
thymocytes from young mice.
Besides decreased survival, another possibility for the decrease
in the DP population could be an inhibition in cellular expansion
or differentiation of CD4 CD8 DN cells. Flow cytometric anal-
ysis of DN cells in aged myr PKB mice revealed that the percent-
age of CD25CD44 (DN3) cells was reduced whereas the
CD44CD25 (DN1) population was increased compared with
wild-type cells (Fig. 4D). The CD25CD44 DN population of
aged myr PKB mice contained a lower fraction of large cells as
determined by forward side scatter analysis, indicating that they
are less cycling. Altogether, these observations suggest that the
decrease in the DP thymocyte population in aged myr PKB mice
could result from a combination of diminished survival of DP cells
and a partial block in expansion/differentiation of DN cells.
Myr PKB supports thymic selection of CD4 T cells
To examine the role of myr PKB in positive selection of thymo-
cytes with a single TCR specificity, we crossed myr PKB mice
with OT2 or OT1 TCR transgenic mice. The majority of OT2 and
OT1 TCR transgenic DP thymocytes bear TCRs specific for OVA
peptides presented by MHC class II or class I molecules, such that
they are selected into the CD4 or CD8 lineage, respectively (33,
34). In myr PKB OT2 double transgenic mice (Fig. 5), we detected
a marked increase in the percentage and number of CD4 SP cells
but not CD8 SP thymocytes compared with OT2 mice not harbor-
ing myr PKB. These CD4 SP thymocytes were fully mature as
evidenced by the expression of the TCR transgenic V2 chain,
CD69, CD5, and HSA, i.e., surface Ags that are up- or down-
modulated when positively selected DP thymocytes mature to SP
cells. Because staining profiles of OT2 myr PKB CD4 SP cells
were comparable to those of OT2 CD4 SP cells, myr PKB en-
hances the efficiency of CD4 development.
The effect of myr PKB on positive selection of CD8 lineage
cells was investigated in myr PKB OT1 double transgenic mice
Table I. Myr PKB mice show a reduction in thymus size, CD8 T cell numbers, and increased CD4:CD8 ratio with agea
Thymus Spleen
Total CD4 DP CD8 Total CD4 CD8
CD4:CD8 ratio
wt PKB/
wt (cell no.  107)
4–12 wk 16.19 (6.51) 1.26 (0.79) 13.86 (5.85) 0.45 (0.30) 13.85 (6.06) 2.38b (1.39) 1.10 (0.79)
3–12 mo 6.28c (2.92) 0.42 (0.35) 5.67c (2.91) 0.11 (0.10) 10.61 (4.79) 1.84b (1.23) 0.77c (0.59)
PKB tg
4–12 wk 17.13 (6.70) 1.47 (0.71) 14.36 (6.39) 0.67 (0.35) 14.62 (4.18) 4.67b (2.30) 0.94 (0.61) 2.2 4.9
3–12 mo 4.38c (2.16) 0.45 (0.30) 3.77c (2.11) 0.13 (0.08) 11.38 (5.09) 4.51b (2.81) 0.40c (0.18) 2.4 11.3
a Cell numbers from thymi (n  28) and spleens (n  29) from wild-type or myr PKB heterozygous mice aged either 4–12 wk or 3–12 mo were determined and cells were
stained for CD4 and CD8 expression to detect T cells. Given are absolute cell numbers for the indicated subpopulations (107) and the CD4:CD8 ratios from pooled young or
aged mice. wt, wild type; tg, transgenic.
b Student’s t test, p  0.001.
c Student’s t test, p  0.01.
FIGURE 2. Analysis of cell sub-
sets in thymus and peripheral lym-
phoid organs from myr PKB mice.
Cell suspensions from (A) thymus and
(B) spleen and LNs of 8-wk-old mice
were stained for CD4 and CD8 ex-
pression. Percentages of the individ-
ual subpopulations are indicated. His-
tograms in A show expression of
TCR, CD5, and CD69 after gating on
DP thymocytes.
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(Fig. 6, A and B). Selection of OT1 CD8 SP T cells was not en-
hanced or even reduced in myr PKB OT1 mice. Interestingly, in
50% of myr PKB OT1 mice, a strong increase in the percentage
and absolute cell number of OT1 CD4 T cells was observed.
Thymi from OT1 myr PKB mice that did not show an overselec-
tion of CD4 T cells phenotypically looked like OT1 wild-type
mice but DP cells showed enhanced reactivity to deleting stimuli
(see Fig. 7C). OT1 CD4 SP cells were phenotypically mature as
assessed by expression of TCR transgenic chains, CD69 and CD5
which were comparable to mature CD8 SP T cells from OT1 mice
(Fig. 6A). In parallel, in spleens from OT1 myr PKB mice a 3- to
4-fold increase in OT1 V2 TCRhighCD4 cells and a decrease in
OT1 CD8 T cells was observed (Fig. 6B). Because the degree of
CD4 overselection was variable, we analyzed two other myr PKB
lines crossed with OT1 mice, with similar expression levels of the
PKB transgene, to exclude a dominant genetic effect from back-
ground genes. In these crosses maturation of CD4 OT1 T cells
was also observed in a high percentage of, but not in all, mice (data
not shown), indicating that CD4 overselection is linked to molec-
ular mechanisms induced by myr PKB. Altogether, the data from
the OT2 and OT1 experimental models suggest that myr PKB
supports the selection and maturation toward the CD4 lineage.
Effects of myr PKB on negative selection
To investigate the role of myr PKB in negative selection, we
crossed myr PKB mice with HY TCR transgenic mice. In these
mice, thymocytes are positively selected in female, but negatively
selected in male mice (35). The latter results in small thymi mainly
due to the marked deletion of DP thymocytes whereas positively
selecting HY female mice show an increase in the CD8 SP pop-
ulation consistent with the recognition of MHC class I molecules
by the HY TCR (Fig. 7A). In myr PKB HY double transgenic
female mice, cell numbers for HY-specific CD8 SP thymocytes, as
determined with the T3.70 mAb (recognizing the transgenic V-
chain), were comparable to HY female mice but numbers of
CD4T3.70 cells were increased 3- to 4-fold. This enhanced
selection of CD4 T cells is similar to our observations in OT2 and
OT1 TCR myr PKB mice. In negatively selecting male myr PKB
HY double transgenic mice, on an average a 2- to 3-fold increase
in the numbers of HY-specific DP and CD8 T cells was detected
as well as a 2- to 4-fold increase in peripheral CD4 and CD8 T
cells expressing autoreactive TCRs (data not shown). Although
total cell numbers in male myr PKB HY mice were still much
lower than in female mice, myr PKB has a definite attenuating
effect on negative selection.
Because the HY system provides a very strong, early deletion
stimulus, we investigated other model systems of negative selec-
tion. First we analyzed deletion mediated by endogenous superan-
tigens (SAgs). Myr PKB mice (on C57/BL6 background) were
bred with DBA/2 and CBA/J mice carrying the endogenous mouse
mammary tumor viruses Mtv 6, 8, and 17, which, in presence of
I-E molecules, induce deletion of SAg-reactive T cells bearing
V5 and V11 TCRs (45). In analyses as shown in Fig. 7B, we did
not detect a myr PKB-dependent difference in the deletion of SAg-
reactive V5 or V11 CD4 T cells in the thymus or periph-
ery, suggesting that myr PKB does not alter in vivo negative se-
lection of SAg-reactive T cells.
The effect of myr PKB on negative selection in OT1 and OT2 mice
was tested by culturing thymocytes from 6- to 7-wk-old mice with
TCR-specific agonistic peptides (46). As depicted in Fig. 7C, myr
PKB distinctly enhanced negative selection induced by OVA peptide
257–264 in OT1 mice. In contrast, deletion of thymocytes from OT2
mice, induced by OVA peptide 323–339, on an average was not al-
tered by myr PKB expression. Thus, in analysis of four experimental
models, myr PKB expression has differential effects, either partially
blocking, enhancing, or leaving negative selection unaltered.
Molecules affected by myr PKB expression
To define molecular events that could mediate the enhanced pro-
liferation of thymocytes and the increase in maturation of CD4
lineage cells, we analyzed the activity of the MAPK Erk and the
Src family kinase Lck which have been shown to be central reg-
ulators of thymocyte selection and lineage choice. Strong and pro-
longed Lck and Erk signaling in particular favor development of
the CD4 lineage but are needed less so for differentiation to the
FIGURE 3. Myr PKB thymocytes are hyper-
reactive against TCR stimulation and less sensi-
tive to inhibition by CsA, FK506, MEK, and Src
kinase inhibitors. A, Equal numbers of total thy-
mocytes from wild-type or myr PKB heterozy-
gous mice were activated with different concen-
trations of platebound anti-CD3 mAb, and
proliferation was measured by [3H]thymidine in-
corporation. B, Thymocytes were cultured with
PMA only (50 ng/ml), PMA plus ionomycin (P/
IO, each 50 ng/ml), or anti-CD3 mAb (CD3, 5
g/ml) in the absence or presence of calcineurin
inhibitors CsA (200 ng/ml) or FK506 (FK, 200
ng/ml). C and D, Thymocytes were stimulated
with anti-CD3 mAb (5 g/ml) in the absence or
presence of MEK inhibitor PD98059 or Src ki-
nase inhibitor PP1 in concentrations as given.
Data show the percent of maximal proliferation
obtained by anti-CD3 stimulation alone, which
was set as 100%. In A–D proliferation was mea-
sured after 48 h and data represent averages from
triplicate cultures from two to three individual
wild-type or myr PKB transgenic mice.
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CD8 lineage (47). When freshly isolated thymocytes were ana-
lyzed for Erk activation (Fig. 8A, top panel), myr PKB thymocytes
showed higher endogenous levels of phospho-Erk than wild-type
thymocytes. Furthermore, stimulation of thymocytes with anti-
CD3 mAbs (Fig. 8B) led to stronger and notably longer-lasting Erk
activation in myr PKB transgenic thymocytes. In addition, the lev-
els of activated c-Raf, an upstream kinase of Erk, were also ele-
vated showing that myr PKB acts as a positive regulator of the
Raf-Mek-Erk signaling cascade.
For analysis of Lck activation, we first used anti-phosphotyrosine
mAb in Western blots and observed that in rested nonstimulated PKB
transgenic thymocytes, tyrosine phosphorylation of Lck was as strong
as in wild-type thymocytes after stimulation with anti-CD3 mAbs
(Fig. 8B). Because phosphorylation can either activate or down-mod-
ulate Lck catalytic activity (48), the enhancement of Lck activity by
myr PKB was confirmed by Lck kinase assay (Fig. 8B). As observed
for Erk, increased Lck activity could also be detected in freshly iso-
lated myr PKB thymocytes using the Lck kinase assay and Abs that
detect the activating tyrosine 394 phosphorylation of Lck (Fig. 8A,
middle and bottom panels). Thus, signals whose intensity and duration
favor selection toward the CD4 lineage are clearly enhanced in myr
PKB thymocytes and are likely to contribute to the observed increase
in the selection of CD4 lineage cells found in myr PKB TCR
transgenic mice.
In this context, we also studied the activation of the c-cbl proto-
oncogene which is highly expressed in thymocytes. Cbl-c has been
shown to be an important regulator of TCR signaling with both a
positive regulatory function as an adapter molecule and a negative
FIGURE 4. A–C, Effects of myr PKB on survival of thymocytes and peripheral CD4 T cells. A, Thymocytes from 6-wk-old mice were cultured in
medium with 10% FCS or medium without FCS or were treated with PMA (50 ng/ml), ionomycin (IO, 50 ng/ml), anti-CD3 mAb (10 g/ml), dexameth-
asone (dex, 1 nM), etoposide (1 M), UV irradiation (0.01 J/cm2), or anti-fas mAb (3 g/ml). The percentage of live (7-AAD- and annexin V-negative)
cells was determined on day 1. B, Increased survival and reduced apoptosis in peripheral myr PKB CD4 T cells. CD4 T cells from wild-type and myr
PKB mice were cultured in medium only containing 10% or 1% FCS or were treated with C2-ceramide (2 M), dexamethasone (1 nM), gamma irradiation
(0.3 Gy), or UV irradiation (0.01 J/cm2) as indicated and live cells were determined on days indicated. Data were calculated from three individual mice
and are representative of three independent experiments. C, Thymocytes from aged mice (7 mo) were cultured in medium with 10 or 1% FCS or
were treated with PMA (50 ng/ml), anti-CD3 mAb (10 g/ml), dexamethasone (dex, 3 nM), etoposide (0.1 M), or anti-fas mAb (9 g/ml) and live
cells were determined on day 1. D, CD44/CD25 profiles of DN thymocytes from 10-mo-old wild-type and myr PKB transgenic mice. Isolated DN
cells were stained with anti-CD44 and anti-CD25 mAbs and analyzed by FACS. The percentage of cells present in each area is indicated. Histograms
show cell size distribution within the CD25CD44 population of wild-type and myr PKB transgenic mice as measured by FACS. Numbers give
the percent of large cells.
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function, inducing the degradation of proteins by its ubiquitin li-
gase activity (49). As shown in Fig. 8B, TCR triggering of thy-
mocytes induces phosphorylation of Cbl-c. Interestingly, myr PKB
enhanced the phosphorylation of Cbl-c suggesting that one way in
which PKB potentiates the Erk signaling cascade could be via
activation of Cbl-c.
Increased activity of Lck, Erk, and possibly Cbl-c most likely
contribute to the enhanced proliferation of myr PKB thymocytes.
Because myr PKB T cells proliferated in the presence of the cal-
cineurin inhibitors CsA or FK506 (Fig. 3), we analyzed phosphor-
ylation and thus inactivation of GSK3, which has been shown to
oppose nuclear NFAT localization (50). We found that TCR trigger-
ing in normal thymocytes leads to fast and transient phosphorylation
of GSK3. However, in myr PKB thymocytes, phosphorylation of
GSK3 is not only stronger but is also sustained over a much longer
period (Fig. 8B). This suggests that a sustained block of GSK3 activity
by myr PKB may render residual low calcineurin activity in the pres-
ence of CsA or FK506 sufficient to allow proliferation of myr PKB
thymocytes in the presence of these immunosuppressants.
PKB is recruited to membrane lipid rafts after TCR/CD3
stimulation
Glycosphingolipid-enriched microdomains, also known as mem-
brane lipid rafts or low density detergent insoluble glycolipid-rich
membrane domains, are important structural membrane elements
for the initiation of TCR-mediated signaling (51). To define how
myr PKB could regulate the activation of Lck and Erk, we studied
the membrane localization of the transgenic protein. Low density
detergent insoluble fractions and heavy soluble fractions from
freshly isolated thymocytes were separated by ultracentrifugation
and analyzed by Western blotting (Fig. 8C). Whereas endogenous
PKB in transgenic and wild-type thymocytes was found only in the
soluble fractions, transgenic phosphorylated PKB was localized
predominantly in the lipid raft fraction. The latter was identified by
the presence of the transmembrane adapter proteins, phosphopro-
tein associated with glycosphingolipid-enriched microdomains
(PAG) (52) and LAT (53). Similar results were obtained for pe-
ripheral CD4 T cells (Fig. 8D); however, in CD4 T cells, phos-
phorylated myr PKB was distributed in both insoluble and soluble
fractions. To analyze whether the presence of myr PKB in lipid
rafts is a feature of TCR-mediated activation, we studied localiza-
tion of PKB after TCR/CD3 stimulation (Fig. 8D, lower two pan-
els). Intriguingly, we found that after TCR stimulation, activated
phosphorylated PKB is associated with lipid rafts in wild-type
CD4 T cells similar to transgenic PKB. These results suggest a
central role for PKB in TCR-induced formation of signaling com-
plexes within lipid rafts.
Discussion
The purpose of this study was to explore how the serine threonine
kinase PKB affects T cell development and T cell activation. Using
transgenic mice, we find that membrane-targeted PKB influences
positive and negative selection of thymocytes, survival, and acti-
vation/proliferation of T cells. Proteins that are involved in myr
PKB-mediated signal transduction include Lck, Raf, and Erk as
well as Cbl-c and GSK3, molecules that are known to set thresh-
olds in thymocyte selection and T cell activation. According to the
current models of selection, strength and duration of TCR-medi-
ated signaling determine lineage commitment or efficiency of se-
lection of CD4 or CD8 T cells (47, 54), whereby strong or
long-lasting signals favor CD4 and weaker or short signals CD8
maturation. In particular, experiments using thymic organ culture
(55, 56) and Lck transgenic mice (57, 58) have demonstrated that
relatively small alterations in intrathymic Lck activity can signif-
icantly affect the CD4/CD8 lineage decision. Likewise, several
studies using genetically modified mice and in vitro differentiation
systems have shown that the strength/duration of Raf-Mek-Erk
signaling regulates positive selection, lineage commitment, and
negative selection (47). In this study, we observe in three different
TCR transgenic systems that myr PKB promotes positive selection
of CD4 T cells. In OT2 TCR transgenic mice, the positive cross-
talk of myr PKB on Lck-Raf-Erk signaling thus could increase the
efficiency of CD4 selection or even allow some DP thymocytes to
acquire the necessary threshold for selection, rescuing them from
“death by neglect.” We were unable to detect a reproducible sig-
nificant effect of myr PKB on the maturation of OT2 or OT1 CD8
T cells. In view of the fact that myr PKB strengthens Lck-Erk
activation, TCR signals might lie above the threshold levels re-
quired for maturation of CD8 T cells. In contrast, stronger Lck-
Erk signals could drive a high proportion of DP cells from OT1
myr PKB double transgenic mice to develop into CD4 T cells, as
we indeed observed in some mice. The variability in overselection
of CD4 cells in OT1 mice, although the underlying mechanisms
are unresolved, is most likely connected to myr PKB activity be-
cause we observed it in three myr PKB lines crossed to OT1 mice
(data not shown). To date, we could not discriminate whether over-
selection of OT1 CD4 T cells is due to an initial switch of some
DP cells to the CD4 lineage or rather a rescue of CD8 committed
CD4CD8low cells due to enhanced/prolonged Lck-Erk signaling.
This also applies for the increased selection of CD4 T cells seen
FIGURE 5. Enhanced positive selection of CD4 T cells in myr PKB
OT2 TCR double-transgenic mice. Thymi from 8-wk-old myr PKB mice
crossed with OT2 TCR transgenic mice were stained for CD4 and CD8
expression. Percentages of cells in each quadrant are given. Histograms
show expression of the transgenic TCR V2 chain, CD69, CD5, and HSA
on DP (thin line) and CD4 SP thymocytes (bold line). Dotted line indicates
isotype control staining. Total cell numbers and quantitation of DP, CD8, and
CD4 SP cells with comparable high expression of the OT2 TCR-specific V2
chain were for OT2 littermate mice (n  7, total 9.27  107  1.38, DP
4.70  107  1.2, CD4 SP 1.90  107  0.78, CD8 SP 0.13  107  0.10)
and for OT2 PKB transgenic mice (n  9, total 12.07  107  2.97, DP
6.35 107 1.15, CD4 SP 4.06 107 1.49, CD8 SP 0.17 107 0.07).
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in OT2 and HY female mice expressing the transgene. In the case
of OT1 mice, myr PKB clearly enhanced negative selection in-
duced by peptide Ag, arguing for a higher sensitivity of OT1/myr
PKB DP cells. Therefore, it is also imaginable that some DP cells
that were destined for deletion might escape negative selection and
mature instead to CD4 T cells. Negative selection not only op-
erates at the DP stage but also at the level of semimature
CD4CD8low cells, detecting a role for fas-mediated deletion of
these semimature cells depending on the Ag dose (59). Defects in
fas-induced deletion of peripheral T cells have been detected in
PTEN mutant (14, 15) and gag-PKB transgenic mice (60). Al-
though deletion mediated by endogenous SAgs and the response of
thymocytes to fas ligation in vitro was not affected by myr PKB in
mice with heterogeneous TCRs, an effect of myr PKB on deletion
of CD4CD8low cells in OT1 mice cannot be totally excluded.
Maturation of DP cells is initiated by the ligation of the TCR
and a number of coinducer/costimulatory receptors including
CD28 (61) and the net effect of these interactions will decide
whether DP cells mature or undergo apoptosis. Interestingly, in a
recent report it was shown that CD28 coengagement of DP cells
can either induce CD4 T cell maturation or negative selection,
depending on the intensity of CD28 costimulation (62). Assuming
that myr PKB reflects some aspects of CD28 signaling in thymo-
cytes, it is more conceivable that subtle differences in myr PKB
expression and modification of downstream target proteins in in-
dividual cells could have differential effects on selection.
Considering that myr PKB inhibits the activity of GSK3, a ki-
nase identified in the regulation of nuclear export of NFATc (50),
and supports T cell proliferation in the presence of calcineurin
inhibitors or in the absence of significant calcium mobilization, it
is also conceivable that differential regulation of NFAT proteins
contributes to the altered phenotype in PKB transgenic mice. Var-
ious NFAT family members have been shown to be involved in
thymocyte selection (63–65) and a role for calcineurin in thymic
selection and activation has been reported in mice expressing a
constitutively active form of calcineurin. In these mice, T cells
showed increased TCR sensitivity and calcium-independent pro-
liferation as well as enhanced positive selection of CD4 T cells
(66), similar to what we observe in myr PKB transgenic mice.
Because PKB has multiple targets, as observed in many different
cell systems, future studies also have to address whether other
proteins regulating thymic selection processes such as c-Jun N-
terminal kinase (67), p38 (68), or Notch (69) are affected by
myr PKB.
The influence of myr PKB on negative selection was studied in
four model systems, whereby myr PKB either enhanced, reduced,
FIGURE 6. Myr PKB supports selection of OT1 CD4 T cells. A, Thymi and spleens from 6- to 8-wk-old OT1 mice or myr PKB mice crossed with
OT1 TCR transgenic mice were stained for CD4 and CD8 expression. Percentages for thymocyte and splenic subpopulations are given. Plots for spleens
are gated on OT1 TCR V2high cells. Histograms for thymocytes were gated on CD8 SP (OT1 mice) or CD4 SP cells (OT1/myr PKB/ mice) and show
expression of OT1 TCR-specific V2 and V5 chains and of CD69 and CD5 markers (bold lines). V2 and V5 expression is also shown for DP
thymocytes (thin lines). Dotted line indicates isotype control staining. B, Total cell numbers for thymus and spleen from OT1 myr PKB mice (n  12, data
include CD4 overselecting mice and myr PKB OT1 mice looking phenotypically similar to wild-type OT1 mice) and OT1 mice (n  12) were determined
and the absolute cell numbers for V2-positive (V2high cells in case of mature cells) thymocyte and splenic subpopulations were calculated from
percentages gained by FACS staining.
1292 Myr PKB ENHANCES Lck/Erk ACTIVATION AND CD4 T CELL MATURATION
 at U
niv of Plym
outh Lib Serv/Libr/Em
m
a Brew
er on February 10, 2016
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
or had no effect on deletion. We conclude that the effect of myr
PKB on negative selection is specific for each system analyzed
depending on the timing, the Ag and TCR affinity/avidity, or
whether Ag is presented by MHC class I or MHC class II mole-
cules. Negative selection not only requires a high avidity TCR
stimulus but also costimulatory signals from APCs which poten-
tially can be provided by CD28 (70). For the deletion of different
autoantigens a complex array of variable costimulators seems to be
necessary (71). Because some of these molecules, like CD28 or
Fas, signal via PKB, our results on negative selection in different
model systems might reflect the complexity of molecules and their
different downstream effector molecules as involved in negative
selection.
In repeated in vitro experiments with thymocytes from 6- to
8-wk-old mice, we did not detect very strong differences in apo-
ptosis/survival between wild-type and myr PKB thymocytes for
most stimuli tested. In contrast, peripheral myr PKB T cells
showed better survival and were more resistant to induction of
apoptosis to different reagents. This differential survival effect
could result from small differences in thymocyte survival that can-
not be detected in in vitro assays but are relevant in vivo or to so
far unknown mechanisms that counteract survival functions in thy-
mocytes from myr PKB mice. In a different approach, by gener-
ating Lck-crePtenflox/ mice with T cell-specific deletion of the
tumor suppressor gene PTEN, PKB activity was greatly enhanced
in T cells (15). With regard to survival and negative selection,
Lck-crePtenflox/ mice had defects in negative selection in vivo
using the HY TCR transgenic system but thymocyte apoptosis in
vitro was also not affected when anti-CD3 or anti-fas mAbs were
used. Thus, for certain stimuli in thymocyte apoptosis other mech-
anisms and molecules might be more critical.
In PKB transgenic mice generated using a gag PKB construct,
Jones et al. (24), in contrast, detected a major enhancement of
survival of thymocytes after treatment with various apoptosis-in-
ducing stimuli in vitro. In further contrast to our data, they did not
observe a selection toward the CD4 lineage using the P14 TCR
transgenic mouse model. This discrepancy most likely results from
differences in expression levels or localization of transgenic PKB
in addition to differences in the affinity/avidity of the transgenic
TCR used (72, 73). As pointed out by these authors, the gag PKB
transgenic protein detected in Western blots was much smaller
than the expected gag PKB fusion protein. This is probably due to
cleavage of the gag sequence thus preventing targeting to the
plasma membrane, although elevated levels of phosphorylated
PKB were detected. In this study, we show that in thymocytes myr
PKB is predominantly localized in membrane lipid rafts, in close
proximity to other raft resident proteins that are essential regula-
tors of TCR signaling such as Lck or LAT. In relation to these
data, we favor the view that the different localization of PKB and
immediate availability of target proteins might be the critical fac-
tors that account for the observed differences in thymocyte survival
and selection in the two PKB transgenic systems. The possibility
that localization of PKB modulates its effector functions is further
supported by our finding that survival was clearly enhanced in
peripheral myr PKB transgenic T cells and that myr PKB in CD4
T cells was distributed in insoluble as well as soluble membrane
fractions. Biochemical studies assessing the redistribution of sig-
naling molecules into lipid rafts indicate that positive selection
signals or TCR/CD3 stimulation alone can recruit TCR signaling
components to the lipid raft fraction (51, 74). Recently Hill et al.
(75) detected constitutively active PKB serine 473 kinase activity
enriched in plasma membrane rafts. In this study, we show that
TCR/CD3 stimulation of CD4 T cells leads to redistribution of
active PKB to the lipid raft fraction thus extending and highlight-
ing the involvement of lipid rafts in TCR-mediated PKB signaling.
Collectively, our findings clearly show that PKB plays an im-
portant role in the signal transduction from TCR-initiated signaling
complexes in lipid rafts by influencing the cross-talk between sev-
eral important signaling molecules such as Lck, Erk, Cbl-c, or
GSK3. By enhancing the strength/duration of Lck-Erk signals,
FIGURE 7. A–C, Effects of myr PKB on negative selection. A, Thymi
from female and male HY and HY myr PKB littermate mice were analyzed
by FACS for expression of CD4, CD8, and the HY TCR-specific V-chain
using T3.70 mAb. The percentages for T3.70CD4, T3.70 DP and
T3.70CD8 cells were determined and absolute cell numbers for T3.70
cells were calculated from total cell numbers; HY male mice n  12 and
HY female mice n  7 for wt and PKB transgenic mice. B, Effect of myr
PKB on deletion of SAg-reactive T cells. CD4 T cells from wild-type and
myr PKB transgenic mice on C57/BL6 (B6) background and myr PKB
mice crossed to DBA/2 and CBA/J mice (F1 generation) were analyzed for
V5 and V11 expression. Mice were assayed at 5 wk after birth. C,
Influence of myr PKB on peptide Ag induced deletion of OT1 and OT2 DP
thymocytes. Thymocytes from OT1 and OT2 mice (wt, broken lines) and
OT1/myr PKB or OT2/myr PKB (tg, full lines) mice aged 6–7 wk were
cultured with the indicated concentrations of TCR-specific OVA peptide
Ag (OVA). On day 1, the percent of live DP cells was determined by
CD4/CD8 labeling and FACS analysis. The graphs show the percent of
peptide-induced deletion of DP cells compared with cultures without Ag.
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PKB is vitally involved in the modulation of activation thresholds
and selectional windows that govern T cell maturation and acti-
vation. Positive effects on Raf-Mek-Erk signaling and possibly dif-
ferential activation of NFAT, via altered calcineurin and GSK3
activities, could also contribute to the development of lymphomas
(Refs. 26, 27, and 76 and our own observations in PKB homozy-
gous mice) and other cancer types, which are thought to result
from overexpression of PKB isoforms.
FIGURE 8. Active PKB localizes in membrane lipid rafts and enhances phosphorylation of Lck, Erk, Cbl-c, and GSK3. A, Freshly isolated thymocytes
from control (wt) and myr PKB transgenic mice (tg) were lysed immediately and protein extracts were analyzed by Western blot for activation of PKB
and Erk (top panel) and Lck (tyrosine 394, middle panel) using phosphospecific Abs. Blots were reprobed for actin and Lck to control protein loading. In
the bottom panel, Lck tyrosine kinase activity from freshly isolated thymocytes was determined by immune complex kinase assay. In addition to auto-
phosphorylation of Lck enolase was used as an indicator of transphosphorylation activity. B, Thymocytes from myr PKB and wild-type mice were rested
for 2 h in 1% FCS medium before activation with anti-CD3 mAb for the time period indicated. Activation of Erk, Raf, and GSK3 were determined in
Western blot using phosphospecific Abs. Activation of Lck and Cbl-c was analyzed with anti-phosphotyrosine mAb. Protein content was controlled by
reprobing blots with anti-Cbl-c, anti-Lck, and anti-actin Abs. In the lowest panel, Lck was immunoprecipitated and Lck activity was determined by kinase
assay. C, Localization of active PKB in lipid rafts. Indicated proteins in detergent insoluble lipid raft fractions (1 and 2) and detergent soluble fractions
(3 and 4) isolated from thymocytes from wild-type and myr PKB mice were detected by Western blot. In the anti-PKB blot, the lower band corresponds
to endogenous (end) PKB, the upper band to transgenic (tg) PKB. D, PKB translocates into lipid rafts after TCR/CD3 stimulation. Proteins in lipid raft and detergent
soluble fractions from LN CD4 T cells, either unstimulated (upper three panels) or stimulated for 30 min with anti-CD3 mAb (lower two panels), were detected
as described in C. Note that after activation, endogenous PKB shows a mobility shift running at the same height as transgenic PKB.
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